FDA-cleared profile

Rapid MLS

iSchemaview Inc.

Brain midline-shift measurement on adult non-contrast CT

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Brain midline-shift measurement on adult non-contrast CT
FDA source Exact FDA submission Checked 2026-09-05
Intended users
Medical professionals using midline shift as a clinical metric
FDA source Exact FDA submission Checked 2026-09-05
Care setting and population
Adult brain CT assessment, including hemorrhage, tumor and traumatic brain injury contexts
FDA source Exact FDA submission Checked 2026-09-05
Workflow role
Measurement or quantification
FDA source Exact FDA submission Checked 2026-09-05
Required input
DICOM non-contrast head CT in adults
FDA source Exact FDA submission Checked 2026-09-05
Output and human action
Color overlay showing expected and indicated midline at the Foramen of Monro; quantitative JSON measurement in millimeters; reports and DICOM Secondary Capture series
FDA source Exact FDA submission Checked 2026-09-06
Limitations
Results are not intended for standalone clinical decisions and do not replace clinical assessment of NCCT cases
FDA source Exact FDA submission Checked 2026-09-05

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243378
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-05

NCCT only for this module; the controlled CT/CTA category does not imply CTA input.

Anatomy
Brain
FDA source Exact FDA submission Checked 2026-09-05
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-05-28
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
NCCT processing module within Rapid Platform, with command-line interface and DICOM/JSON outputs
FDA source Exact FDA submission Checked 2026-09-06
Deployment and data flow
On-premise
Public source Exact FDA submission Checked 2026-08-13

Preserved prior source-backed baseline deployment category. Current summary establishes Rapid Platform integration, not a detailed hosting topology; current commercial installation requires confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-05

Standards listed in a regulatory summary do not establish a current scoped security certification or installation-specific controls.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-05

End-user onboarding, large-shift review guidance and local competency requirements remain unestablished.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-05

Site acceptance could audit measurement outliers and routing failures; no specific monitoring feature or SLA established.

Family midline-shift visualization

RapidAI's hemorrhagic-care page specifically describes Rapid MLS measurement and visualization

product family · checked 2026-09-05

Other modules' hemorrhage volume, triage and reimbursement claims are not attributed to MLS.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
Standalone validation used 153 NCCT cases from 13 sites (11 US, 2 outside US), ages 26-93, compared with three-expert reference. FDA-reported Rapid MAE was 0.7 mm versus expert average pairwise MAE 1.0 mm. Test cases were separate from development data.
FDA source Exact FDA submission Checked 2026-09-06
Reported sensitivity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-05

Measurement-error evaluation does not establish a diagnostic sensitivity for a binary clinical condition.

Reported specificity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-05

A diagnostic specificity was not established by the reviewed measurement study.

Midline-shift mean absolute error

0.7 mm

Difference from three-expert reference midline shift in 153 adult NCCT cases, 13 sites, age 26-93.

Tested version: Rapid MLS in K243378; release number not stated

K243378 standalone midline-shift validation

Blinded standalone comparison with three-expert reference, data separate from development · Adults age 26-93; GE, Philips, Toshiba and Siemens NCCT

exact submission · Tested version: Rapid MLS in K243378 · n=153 · 13 sites · Independence not established

K243378

Automated midline-shift measurement evaluation reported in AJNR

Retrospective multicenter expert-reference comparison · 153 adult artifact-free CT cases with intracranial pathologies from 13 centers

product family · Tested version: Rapid MLS; exact version not established in reviewed abstract · n=153 · 13 sites · Independence not established

PMID:42481415 · doi:10.3174/ajnr.A9540

Abstract reports 0.8 mm MAE and tendency to underestimate shifts greater than 10 mm. Not substituted for FDA 0.7 mm result. Cohort may overlap regulatory data; not counted as independent replication.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-06

Exact-name price/procurement search did not yield a reviewed primary-source module quote; platform bundle costs remain unestablished.

Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-09-06

No applicable payer policy reviewed. RapidAI page references to reimbursement for other modules are not Rapid MLS coverage.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
19Fields reviewed
11Source classes checked
1Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

Stored PubMed candidate and live abstract reviewed; retained as family evidence with uncertain version and possible regulatory cohort overlap. Stored trial array empty. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-06.

Alternatives

Related tools to compare

FDA-cleared K250354

Viz Subdural+, Viz SUBDURAL PLUS

Viz.ai, Inc.

Viz Subdural+ labels, visualizes, and quantifies subdural collections from single-time-point non-contrast head CT, reporting collection grayscale value, total volume, widest...

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-10